Showing 2451-2460 of 5909 results for "".
- Amgen to Buy Horizon Therapeutics in Deal Worth $27.8 Billionhttps://modernod.com/news/amgen-to-buy-horizon-therapeutics-in-deal-worth-278-billion/2481288/Amgen announced it is acquiring rare disease drug company Horizon Therapeutics, maker eye disease drugs Tepezza and Uplizna, in a deal valued at $27.8 billion. The company will pay $116.50 in cash per share, a premium of 19.7% to Horizon’s last closing price. Tepezza (teprotumumab
- Re-Vana Therapeutics Raises $11.9 Million to Advance Drug Delivery Productshttps://modernod.com/news/re-vana-therapeutics-raises-119-million-to-advance-drug-delivery-products/2481266/Re-Vana Therapeutics announced the closure of its Series A round with $11.9 million in funding, an oversubscription of $4 million. The proceeds will advance the development of Re-Vana's novel and proprietary photo-crosslinked EyeLief, EyeLief-SD, and OcuLief 
- Kala Pharmaceuticals Submits of Investigational NDA for KPI-012 for the Treatment of Persistent Corneal Epithelial Defecthttps://modernod.com/news/kala-pharmaceuticals-submits-of-investigational-nda-for-kpi-012-for-the-treatment-of-persistent-corneal-epithelial-defect/2481262/Kala Pharmaceuticals announced the submission of an investigational new drug application (NDA) to the FDA for KPI-012 for the treatment of persistent corneal epithelial defect (PCED). Subject to acceptance of the IND by the FDA, Kala remains on-track to initiate a phase 2b cli
- New UCI-Led Study Shows Repeated Stress Accelerates Aging of the Eyehttps://modernod.com/news/new-uci-led-study-shows-repeated-stress-accelerates-aging-of-the-eye/2481260/New research from the University of California, Irvine, suggests aging is an important component of retinal ganglion cell death in glaucoma, and that novel pathways can be targeted when designing new treatments for glaucoma patients. The study, titled, “
- FDA Grants Breakthrough Therapy Designation for Iveric Bio's Avacincaptad Pegol for Geographic Atrophyhttps://modernod.com/news/fda-grants-breakthrough-therapy-designation-for-iveric-bios-avacincaptad-pegol-for-geographic-atrophy/2481251/Iveric bio announced that the FDA has granted Breakthrough Therapy designation for avacincaptad pegol (ACP, also known as Zimura), a novel investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). To date, A
- Study: Vision Impairment is Associated with as Many as 100,000 US Dementia Caseshttps://modernod.com/news/study-vision-impairment-is-associated-with-as-many-as-100000-us-dementia-cases/2481238/Up to 100,000 US dementia cases could have potentially been prevented with improved eye care, according to a National Institute on Aging (NIA)-funded study published in JAMA Neurology. While the search for breakthrough drugs or interventions that could be treatments f
- FDA Accepts Tarsus' New Drug Application for TP-03 for Treatment of Demodex Blepharitishttps://modernod.com/news/fda-accepts-tarsus-new-drug-application-for-tp-03-for-treatment-of-demodex-blepharitis/2481235/As part of its third quarter earnings report, Tarsus Pharmaceuticals announced that the FDA has accepted the company's new drug application (NDA) for TP-03 for the treatment of Demodex blepharitis. The Prescription Drug User Fee Act (PDUFA) target action da
- MediPrint Ophthalmics Announces It Has Initiated Its SIGHT-2 Phase 2b Clinical Study for Its Lead Assethttps://modernod.com/news/mediprint-ophthalmics-announces-it-has-initiated-its-sight-2-phase-2b-clinical-study-for-its-lead-asset/2481231/MediPrint Ophthalmics announced it has initiated its SIGHT-2 dose-finding phase 2b study for its proprietary drug-eluting contact lens for glaucoma. This is the second study in its SIGHT (Sustained Innovative Glaucoma and ocular Hypertension Treatment) clinical program aimed at treating
- Nicox Outlines Future Development and Partnering Plans for NCX 470https://modernod.com/news/nicox-outlines-future-development-and-partnering-plans-for-ncx-470-in-glaucoma/2481228/Nicox SA announced future development and partnering plans for NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop, currently in phase 3 development for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. “Our market research&nbs
- Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI Surgical System in Pseudophakic Glaucoma Patientshttps://modernod.com/news/sight-sciences-announces-publication-of-clinical-data-demonstrating-standalone-effectiveness-of-the-omni-surgical-system-in-pseudophakic-glaucoma-patients-with-uncontrolled-pressure-following-a-previous-combination-cataract-stent-procedure/2481221/Sight Sciences announced International Ophthalmology has published clinical data demonstrating the safety and effectiveness of the OMNI Surgical System as a minimally invasive, implant-free standalone (not in combination with cataract surgery) glaucoma procedure for pseudophaki